PMD20 PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS: A FOCUS-ED APPROACH  by Gold, KF et al.
306 Abstracts
compare patient-reported outcomes in two statins (Statin A and
Statin B). Medwatch is the Food and Drug Adminstration’s
(FDA) program for reporting serious reactions with drugs and
other medical products. Consumer reports are an increasing
number of those drug safety reports and through March 30,
2003, make up more than 27% of the total Medwatch reports.
METHODS: The QSCANTM software was used to compare the
consumer spontaneous reports of two statins (Statin A and Statin
B), using a signal detection methodology, the proportional
reporting ratio (PRR). The two statins were also individually
compared to the class of statin drugs. RESULTS: Statin A had
32,371 consumer reports of adverse events, and Statin B had a
total of 21,895 consumer reports through the ﬁrst quarter of
2003. Report dates were comparable for the two statins. Com-
pared to Statin B, Statin A had a signiﬁcantly higher proportion
of reports for arterial occlusion, cardiac arrest, increased blood
cholesterol, coronary artery surgery, transient ischemic attack,
and aggravated condition. Statin B had a signiﬁcantly higher
PRR for burning sensation (within nervous system disorders),
diabetes mellitus, and decreased blood pressure. The signiﬁcantly
elevated PRRs for Statin B persisted when compared to all other
statins, whereas Statin A appeared similar to the rest of the statin
class for these particular adverse event reports. CONCLU-
SIONS: Using drug safety signal detection data mining technol-
ogy of consumer-driven spontaneous reports, it is possible to
identify possible areas of drug differention between two drugs
or a single drug and an entire drug class. Consumer Medwatch
reports are spontaneous drug adverse event reports that are vol-
untarily submitted by the consumer and may be an informative
source of real-life patient reported outcomes.
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A survey of European Regulators conducted by the ERIQA
Group evidenced the need of training on HRQL and PRO. To
meet this need ERIQA in collaboration with the Cochrane
HRQL Methods Group proposed an Educational Program on
PRO and HRQL using the Workmats, designed for interactive
learning within a group to facilitate the understanding of key
concepts. In 2002 and 2003, regulators were trained in France
(AFSSAPS, ANAES), in Belgium (INAMI) and in the US (FDA).
Members of the Cochrane Collaboration were also trained
during the Stavanger and Barcelona colloquia. OBJECTIVES: To
assess the relevance and the impact of the Workmats training
from the regulators perspective. METHODS: We provided an
evaluation form at the end of each session. Seven questions were
asked addressing the content, the format and the attitude
towards PROs in the future. RESULTS: Eighty persons were
trained: thirty-two members of the Cochrane Collaboration and
48 regulators. To Question 2: Did you learn some useful infor-
mation? Ninety-seven and one-half percent answered Yes. To
Question 3: Did the workshop come up to your expectations?
Ninety-one and one-third percent answered Yes, 6.2% No and
2.5% did not answer. To Question 6: will this training change
your way of evaluating ﬁles? Ninety-oner and three-ﬁfths percent
of the regulators said Yes, 4.2% said No and 4.2% did not
answer. To Question 7: Would you recommend this workshop
to your colleagues? Sixty-eight and seven-tenths percent said yes,
21.3% said maybe, 3.7% said No and 6.3% did not answer.
CONCLUSION: Workmats proved to be a useful training tool
by providing basic information on PROs and enabling regula-
tors to better understand the ﬁeld. The fact that 91.6% of the
attendees said that this training might change their way of
reviewing ﬁles and 90% might recommend the session to 
colleagues encouraged us to plan sessions in 2004 in other 
European countries and the US.
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OBJECTIVES: In the absence of a disease-speciﬁc instrument,
existing generic proﬁles may not be sensitive enough to measure
health-related quality of life in certain disease populations. In
addition, instruments developed for other diseases may have
some face validity but are not ideal. The goal of this research is
to develop an approach for rare disease instrument development
given the challenges of available sample and resources.
METHODS: The functional outcomes for clinical understanding
scale (FOCUS) “focuses” on aspects of rare diseases not captured
in validated instruments. A list of outcome domains is ﬁrst gen-
erated for the rare disorder. A validated instrument (“anchor”)
for a disease with some symptoms common to the rare disease
of interest is then identiﬁed. New items are developed in a similar
scale to the anchor instrument in order to allow joint scoring.
Data are collected to assess the validity and reliability for 1) the
anchor instrument; 2) new items (FOCUS) and 3) the anchor
instrument conjoined with the new items. RESULTS: A FOCUS
instrument was developed for Mucopolysaccharidosis II (MPSII;
Hunters Syndrome (HS)), a rare genetic disorder in children. The
childhood health assessment questionnaire (CHAQ) was selected
as the “anchor” instrument. Items of the HS-FOCUS were gen-
erated for MPSII indicators not covered by the CHAQ. Both the
CHAQ and the HS-FOCUS were tested in MPSII patients and
parents. Five of eight FOCUS domains had a Cronbach’s alpha
of at least 0.84 individually. The reliability of the overall CHAQ
score in MPSII patients was comparable to its original sample
(high 0.80s). The reliability of the CHAQ in conjunction with
the HS-FOCUS was superior to each in isolation. The compound
instrument also showed high face, external and statistical valid-
ity. CONCLUSIONS: This example illustrates the potential
success possible using this FOCUS methodology for meeting the
instrumentation needs for rare diseases.
METHODS
METHODS—Patient Preference Studies
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OBJECTIVES: The purpose of this study was to examine dif-
ferences between traders and non-traders and characteristics that
are associated with being a non-trader. When eliciting utilities
using the Time Trade-Off (TTO) method, studies have shown
that we can usually anticipate a high level (15–60%) of non-
traders—those people who are not willing to trade any of their
life for improved health. METHODS: A cross-sectional super-
vised self-administered survey was used to assess the perception
of health-related quality of life (HRQOL) and utilities using the
TTO method in the general population of 3 groups: Caucasian
